{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:30:10Z","timestamp":1787319010907,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152748","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:41:01Z","timestamp":1746272461000},"page":"152748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis"],"prefix":"10.1016","volume":"73","author":[{"given":"J.A.","family":"van der Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Brilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.H.P.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.A.M.","family":"Weel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Lard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.T.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2025.152748_bib0001","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/rheumatology\/37.6.612","article-title":"Combination therapy in rheumatoid arthritis: updated systematic review","volume":"37","author":"Verhoeven","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152748_bib0002","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0003","first-page":"12","article-title":"Reevaluating the therapeutic approach to rheumatoid arthritis: the \"sawtooth\" strategy","volume":"22","author":"Fries","year":"1990","journal-title":"J Rheumatol Suppl"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152748_bib0004","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"9430","key":"10.1016\/j.semarthrit.2025.152748_bib0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"9074","key":"10.1016\/j.semarthrit.2025.152748_bib0006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152748_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000057","article-title":"Rheumatoid arthritis treatment: the earlier the better to prevent joint damage","volume":"1","author":"Monti","year":"2015","journal-title":"RMD open"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152748_bib0008","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2010.179","article-title":"Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis","volume":"6","author":"Hoes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152748_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152748_bib0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jbspin.2009.12.011","article-title":"Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion","volume":"77","author":"Mouterde","year":"2010","journal-title":"Joint Bone Spine"},{"issue":"4 Suppl 73","key":"10.1016\/j.semarthrit.2025.152748_bib0011","first-page":"S44","article-title":"The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis","volume":"30","author":"Hetland","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152748_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152748_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0014","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. 2017;76(6):960\u201377."},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152748_bib0015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152748_bib0016","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","article-title":"Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study)","volume":"71","author":"Wevers-de Boer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152748_bib0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2011-201162","article-title":"Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial","volume":"72","author":"de Jong","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152748_bib0018","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152748_bib0019","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/annrheumdis-2012-202818","article-title":"A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks","volume":"73","author":"den Uyl","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152748_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0021","doi-asserted-by":"crossref","unstructured":"Chatzidionysiou K, Emamikia S, Nam J, Ramiro S. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. 2017;76(6):1102\u20137.","DOI":"10.1136\/annrheumdis-2016-210711"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152748_bib0022","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3899\/jrheum.130019","article-title":"We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better","volume":"40","author":"Volkmann","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152748_bib0023","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152748_bib0024","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2025.152748_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/rheumatology\/35.suppl_2.4","article-title":"Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers","volume":"35","author":"van Riel","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152748_bib0026","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","article-title":"Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score","volume":"35","author":"Prevoo","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152748_bib0027","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152748_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72274-2","article-title":"Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis","volume":"10","author":"Aoki","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152748_bib0029","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/OARRR.S306378","article-title":"Influence of age and sex on disease course and treatment in rheumatoid arthritis","volume":"13","author":"Nilsson","year":"2021","journal-title":"Open Access Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152748_bib0031","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2665-9913(22)00095-9","article-title":"Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis","volume":"4","author":"van Wesemael","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152748_bib0032","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/acr.21978","article-title":"Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients","volume":"65","author":"Heimans","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152748_bib0033","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/acr.20609","article-title":"Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register","volume":"63","author":"Camacho","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152748_bib0034","first-page":"1503","article-title":"A prognostic model for functional outcome in early rheumatoid arthritis","volume":"33","author":"Bansback","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0035","series-title":"Springer texts in statistics","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-7138-7_2","article-title":"An introduction to statistical learning","author":"James","year":"2013"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152748_bib0036","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0009-8","article-title":"Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry","volume":"2","author":"Steunebrink","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152748_bib0038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009742.2011.594964","article-title":"Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression","volume":"41","author":"Dirven","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152748_bib0039","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/art.42245","article-title":"The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"74","author":"Krause","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.semarthrit.2025.152748_bib0040","author":"Verschueren","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152748_bib0041","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152748_bib0042","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2007.073817","article-title":"Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis","volume":"67","author":"Guler-Yuksel","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152748_bib0043","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-012-2136-8","article-title":"Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy","volume":"32","author":"Dirven","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152748_bib0044","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.20251","article-title":"The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies","volume":"51","author":"van Everdingen","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:00:40Z","timestamp":1751580040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"alternative-id":["S0049017225001192"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152748","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152748"}}